Equity Overview
Price & Market Data
Price: $0.70
Daily Change: -$0.0079 / 1.13%
Range: $0.70 - $0.85
Market Cap: $2,533,984
Volume: 170,441
Performance Metrics
1 Week: 3.12%
1 Month: 2.34%
3 Months: -51.34%
6 Months: -68.05%
1 Year: -87.22%
YTD: -30.68%
Company Details
Employees: 7
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company that develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is based in Weston, Florida.